L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer.
about
High levels of aromatic amino acids in gastric juice during the early stages of gastric cancer progressionCurrent status of biomarkers for prostate cancerThe role of L-type amino acid transporter 1 in human tumorsIntegrins in the Spotlight of CancerGenomic profiling of tumor initiating prostatospheres.Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancerPrognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer.Correlation between positron emission tomography findings and glucose transporter 1, 3 and L-type amino acid transporter 1 mRNA expression in primary central nervous system lymphomasGene expression changes with age in skin, adipose tissue, blood and brain.Monoterpene glycoside ESK246 from Pittosporum targets LAT3 amino acid transport and prostate cancer cell growth.Relation of LAT1/4F2hc expression with pathological grade, proliferation and angiogenesis in human gliomas.Synthesis and evaluation of amino acid-based radiotracer 99mTc-N4-AMT for breast cancer imaging.High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomasImaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPETIncreased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma.Relationship between CD147 and expression of amino acid transporters (LAT1 and ASCT2) in patients with pancreatic cancer.Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myelomaL-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia.Analysis of L-type amino acid transporter in canine hepatocellular carcinoma.MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor genemiR-126-3p Inhibits Thyroid Cancer Cell Growth and Metastasis, and Is Associated with Aggressive Thyroid Cancer.Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinomaPrognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors.Study of LAT1 Expression in Brain Metastases: Towards a Better Understanding of the Results of Positron Emission Tomography Using Amino Acid Tracers.Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancerSynthesis and evaluation of 18F labeled alanine derivatives as potential tumor imaging agentsCharacterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptakeHigh Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction.SLC Transporters: Structure, Function, and Drug Discovery.Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma.Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer.ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer.L-type amino acid transporter 1 expression is highly correlated with Gleason score in prostate cancer.The impact of L-type amino acid transporter 1 (LAT1) in human hepatocellular carcinoma.Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics.Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters.Hypoxia and cellular metabolism in tumour pathophysiology.miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.PET Tracers Beyond FDG in Prostate Cancer.Suppression of amino acid transporter LAT3 expression on proliferation of K562 cells.
P2860
Q21133895-935C00D9-E9A7-4AB2-8905-D67522D33CFEQ24600574-0D31BB4E-E82D-4F88-83DE-471846077018Q26775785-1BC29FA8-CFC1-4779-B552-11E26A0D845EQ28066805-CBB3C95E-1D8A-4793-BDD0-F0D6C4E493F0Q33586722-EC254DB5-2C9C-4F7B-A9CA-E62E951C35F1Q33592952-63DF13D6-5DCE-4445-AA64-BFD292CF5464Q33613632-435CC9EE-DB04-4CEC-A2D4-F139E79E5D3DQ33733797-885FEEF8-8944-40F2-B4FE-08979811D96AQ33742819-6DDEF4D4-26A7-4955-9C4A-DCEEAB3BBC31Q33797210-77CA4D2C-267A-4161-B10A-6247E05C8F81Q34175221-32B0CA99-ECD0-4471-936B-E5F903809DD0Q34896422-8D5285A2-BDC2-45AF-9556-28EE13A29A0BQ34998503-0E3B6EE5-8203-4A98-876B-A40074927024Q35021768-92693C64-A0EE-4061-ACE7-90BEF6EAFCCBQ35028079-BE3937B4-59DF-4EE4-B663-C31B827CA4C7Q35440166-3A705A6E-D368-484B-AED4-F78613C71AEBQ35713446-27F5F06A-ACCE-477B-BF8E-5C90198CF77FQ35757977-533A392C-A8ED-49DC-BE16-2CACBEBB81E4Q35774573-081B170D-B5C2-47F4-B74A-8CEFD16A84EDQ35857671-09113BB2-24E8-41EF-8977-CEC653E84F24Q35921263-F5433399-9195-42D9-BC9C-BAC5BD309F7EQ35941321-E95BD769-4C59-4BE3-BC6C-B07553CD96C6Q35941337-C6A7CEC2-732D-4939-8BC3-34CF41E303CEQ36045175-4C16B871-0FF3-4A78-AF8B-4D45A52A9C04Q36166827-AA02D230-AA6D-4899-B7B2-0479BEFAA43BQ36205180-A8C5CFF6-5F5D-4575-8344-B023A137C3C8Q36533826-E6169712-CC46-4262-9DFB-7D0BDF3ECFBEQ37269734-AC470B59-0305-464D-BEF6-632DEE79336AQ37279747-E7AC9A38-33C1-48FF-99C0-06B34C6AF5EFQ37375216-DFB49DB1-B982-4028-A511-0FC98367783BQ37711666-6A08B2FC-83E2-4DBA-AB38-ED88853CA47AQ37711691-C3EE6523-7E86-4408-9121-55CC87ED26A0Q38292729-E61BF519-E8FD-43B7-B591-72FC4D5ED5FCQ38396468-6532173E-8CEF-4013-B114-A2CB6D14C68BQ38476583-83CD4E2A-3D76-4E44-B4D1-66984AD8CF77Q38742764-90F1E6EA-B402-4145-A441-2BFFEEBB81A8Q38772023-5AB6AFBC-2832-4E38-B0A9-4CA12C093060Q38972595-A209CB8C-ED8C-4911-95DD-9EAE67CCD9E1Q39003086-4FE1DA69-A27A-4DB4-9DC2-AD734B4A2790Q39076144-B08684A6-C4D0-4A87-B420-F6144227D626
P2860
L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
L-type amino-acid transporter ...... malignancy in prostate cancer.
@ast
L-type amino-acid transporter ...... malignancy in prostate cancer.
@en
L-type amino-acid transporter ...... malignancy in prostate cancer.
@nl
type
label
L-type amino-acid transporter ...... malignancy in prostate cancer.
@ast
L-type amino-acid transporter ...... malignancy in prostate cancer.
@en
L-type amino-acid transporter ...... malignancy in prostate cancer.
@nl
prefLabel
L-type amino-acid transporter ...... malignancy in prostate cancer.
@ast
L-type amino-acid transporter ...... malignancy in prostate cancer.
@en
L-type amino-acid transporter ...... malignancy in prostate cancer.
@nl
P2093
P1476
L-type amino-acid transporter ...... malignancy in prostate cancer.
@en
P2093
Akinori Ueno
Golam Ferdous
Hitoshi Endou
Isao Okayasu
Shiro Baba
Takefumi Satoh
Takeshi Sakata
Tomoko Muto
Tomoko Tsuruta
Yoshikatsu Kanai
P356
10.1111/J.1440-1827.2008.02319.X
P577
2009-01-01T00:00:00Z